SC
ASMB icon

Stempoint Capital’s Assembly Biosciences ASMB Stock Holding History

Stempoint Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.15M Buy
185,435
+28,707
+18% +$819K 0.99% 33
2025
Q4 		$5.33M Buy
156,728
+90,598
+137% +$2.92M 0.91% 36
2025
Q3 		$1.69M Buy
+66,130
New +$1.45M 0.34% 53

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Stempoint Capital's ASMB Position: Q1 2026 in Review

Stempoint Capital increased its Assembly Biosciences (ASMB) stake by 18% in Q1 2026, buying an estimated $819K and bringing the position to 185,435 shares worth $5.15M. The position accounts for 0.99% of the portfolio, ranked #33.

Stempoint Capital first reported a position in ASMB in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.33M in Q4 2025. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Stempoint Capital held 185,435 shares of Assembly Biosciences worth $5.15M as of Q1 2026.
  • Stempoint Capital bought 28,707 Assembly Biosciences shares in Q1 2026, an estimated $819K.
  • Assembly Biosciences made up 0.99% of Stempoint Capital's portfolio in Q1 2026, its #33 holding.
  • Stempoint Capital first reported a position in Assembly Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Stempoint Capital's Assembly Biosciences position peaked at $5.33M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.